NICE asks Roche to compare RoActemra with Kineret and Remicade in juvenile arthritis
This article was originally published in Scrip
Executive Summary
NICE says it wants more information on the clinical and cost effectiveness of Roche's RoActemra (tocilizumab) for treating systemic juvenile idiopathic arthritis (sJIA) before it decides whether or not to recommend it. The call from the health technology appraisal institute for England and Wales for comparisons with other compounds used to treat sJIA could have implications for Merck and Novartis, both of which have antibody drugs in phase III studies for the disease.